paclitaxel + cisplatin + bevacizumab

This combination chemotherapy and targeted therapy regimen is being investigated by Memorial Sloan Kettering Cancer Center (MSKCC) for the initial treatment of optimal Stage II/III ovarian, primary peritoneal, and fallopian tube cancers. The regimen utilizes a multi-modal delivery approach, combining intravenous (IV) and intraperitoneal (IP) administration. It consists of paclitaxel, a taxane that stabilizes microtubules to inhibit cell division; cisplatin, a platinum-based agent that causes DNA cross-linking; and bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) to inhibit angiogenesis. The Phase II study explored the feasibility and safety of adding bevacizumab to the standard IP/IV paclitaxel and cisplatin backbone, noting potential efficacy but also safety concerns such as bowel obstructions.

Other names

IP/IV paclitaxel, IP cisplatin, and IV bevacizumabBevacizumab with IP/IV Chemotherapy